Literature DB >> 18220965

The influenza virus NS1 protein: inhibitor of innate and adaptive immunity.

A Fernandez-Sesma1.   

Abstract

The influenza virus NS1 protein has been shown to be a multifunctional immune modulator and a virulence factor for this virus. Among its multiple functions are the inhibition of the type I interferon (IFN) system in infected cells, the binding and sequestration of dsRNA, the interference with the host mRNA processing, the facilitation of preferential viral mRNA translation, and the inhibition of dendritic cell (DC) activation. The combination of all these functions makes the NS1 protein a very potent inhibitor of immunity and allows influenza virus to efficiently escape the immune surveillance and to establish infection in the host. There are different domains in the NS1 protein that are required for specific functions, which provides several potential targets for the action of antiviral drugs. Additionally, the crystal structure of both the N-terminal RNA binding domain and the C-terminal effector domain of the NS1 protein have been resolved, potentially allowing for better antiviral drug design. Recent advances in the understanding how viruses are detected by infected cells are unveiling the mechanisms by which the NS1 protein can perform some of its multiple immune modulating activities. In this review the multiple functions of the NS1 protein are discussed and several possible options for drug targets within the influenza virus NS1 protein will be explored. Such drugs could make influenza viruses less efficient at evading the immune system in the host.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18220965     DOI: 10.2174/187152607783018754

Source DB:  PubMed          Journal:  Infect Disord Drug Targets        ISSN: 1871-5265


  35 in total

Review 1.  Postinfluenza bacterial pneumonia: host defenses gone awry.

Authors:  Megan N Ballinger; Theodore J Standiford
Journal:  J Interferon Cytokine Res       Date:  2010-09       Impact factor: 2.607

2.  Novel influenza virus NS1 antagonists block replication and restore innate immune function.

Authors:  Dipanwita Basu; Marcin P Walkiewicz; Matthew Frieman; Ralph S Baric; David T Auble; Daniel A Engel
Journal:  J Virol       Date:  2008-12-03       Impact factor: 5.103

Review 3.  Understanding the focused CD4 T cell response to antigen and pathogenic organisms.

Authors:  Jason M Weaver; Andrea J Sant
Journal:  Immunol Res       Date:  2009-02-07       Impact factor: 2.829

Review 4.  Cross-species virus transmission and the emergence of new epidemic diseases.

Authors:  Colin R Parrish; Edward C Holmes; David M Morens; Eun-Chung Park; Donald S Burke; Charles H Calisher; Catherine A Laughlin; Linda J Saif; Peter Daszak
Journal:  Microbiol Mol Biol Rev       Date:  2008-09       Impact factor: 11.056

5.  Dynamics of influenza virus infection and pathology.

Authors:  Roberto A Saenz; Michelle Quinlivan; Debra Elton; Shona Macrae; Anthony S Blunden; Jennifer A Mumford; Janet M Daly; Paul Digard; Ann Cullinane; Bryan T Grenfell; John W McCauley; James L N Wood; Julia R Gog
Journal:  J Virol       Date:  2010-02-03       Impact factor: 5.103

Review 6.  Innate immune evasion strategies of influenza viruses.

Authors:  Benjamin G Hale; Randy A Albrecht; Adolfo García-Sastre
Journal:  Future Microbiol       Date:  2010-01       Impact factor: 3.165

7.  Why is coinfection with influenza virus and bacteria so difficult to control?

Authors:  Linda S Cauley; Anthony T Vella
Journal:  Discov Med       Date:  2015-01       Impact factor: 2.970

8.  Genetic divergence of influenza A NS1 gene in pandemic 2009 H1N1 isolates with respect to H1N1 and H3N2 isolates from previous seasonal epidemics.

Authors:  Giulia Campanini; Antonio Piralla; Stefania Paolucci; Francesca Rovida; Elena Percivalle; Giovanni Maga; Fausto Baldanti
Journal:  Virol J       Date:  2010-09-01       Impact factor: 4.099

9.  Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice.

Authors:  Jincun Zhao; Jingxian Zhao; Nico Van Rooijen; Stanley Perlman
Journal:  PLoS Pathog       Date:  2009-10-23       Impact factor: 6.823

10.  Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine.

Authors:  Julia Romanova; Brigitte M Krenn; Markus Wolschek; Boris Ferko; Ekaterina Romanovskaja-Romanko; Alexander Morokutti; Anna-Polina Shurygina; Sabine Nakowitsch; Tanja Ruthsatz; Bettina Kiefmann; Ulrich König; Michael Bergmann; Monika Sachet; Shobana Balasingam; Alexander Mann; John Oxford; Martin Slais; Oleg Kiselev; Thomas Muster; Andrej Egorov
Journal:  PLoS One       Date:  2009-06-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.